trending Market Intelligence /marketintelligence/en/news-insights/trending/9Vdc0MPPiABT8sdOBg5G6w2 content esgSubNav
In This List

Clearside Biomedical's eye drug Xipere rejected by US FDA

Blog

Insight Weekly: Banks brace for recession; Europe PE deal values soar; US solar imports rebound

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook


Clearside Biomedical's eye drug Xipere rejected by US FDA

Clearside Biomedical Inc. said the U.S. Food and Drug Administration rejected its application for eye inflammation treatment Xipere.

The company was seeking approval to market Xipere as a treatment for macular edema associated with uveitis, a condition characterized by the buildup of fluid in a part of the eye —leading to vision loss and blindness.

It is estimated that uveitis affects about 350,000 patients in the U.S. and over one million globally; about one-third of patients develop uveitic macular edema.

In its complete response letter, the regulator asked for additional stability data on the new manufacturing process for Xipere, an injectable form of a synthetic corticosteroid called triamcinolone acetonide. Alpharetta, Ga.-based Clearside said it would be able to address the request, plus another for additional data on the clinical use of the delivery system for the medicine, and resubmit its application in the first quarter of 2020.

The company also said the FDA did not identify any efficacy issues and made no requests for further clinical efficacy studies, but did ask to reinspect the drug's product manufacturer.